Lipid Nanoparticles Market Report 2023: R&D Consistency Drives Sector Growth

In 2023, the global Lipid Nanoparticles market is expected to be worth US$ 887.2 million. With rising health concerns about dietary supplements as a result of Covid-19, and rising dietary supplement consumption, the overall demand for Lipid Nanoparticles is expected to grow at a CAGR of 13.6% between 2023 and 2033, reaching around US$ 3,175.5 million by 2033.

Rapid population growth in regions such as Asia Pacific, Europe, and North America is expected to drive demand for products such as pharmaceuticals and healthcare, dietary supplements, functional food, functional beverages, cosmetics and personal care, and others. The high content of omega 3 and omega 6 in lipids is the primary reason for its widespread use in food and beverage products.

Furthermore, rising global prices for fatty acids and other raw materials act as a global barrier to market growth. These price fluctuations are a result of the COVID-19 and the ongoing geopolitical conflict in Europe. The price of fatty acids in North America fluctuated in the first quarter of 2022 due to a decline in demand for fatty acids from the personal care, cosmetic, and food industries. Furthermore, American fatty acid producers had to contend with supply shortages from Asian countries.

However, market participants are focusing on R&D and developing new advancements in Lipid Nanoparticles technology, which is expected to create lucrative opportunities for the market in the near future.

Factors such as the increasing demand for medicines due to high incidence of cancer, chronic diseases, as well as growing focus on physical well-being are expected to propel the sales of pharmaceutical lipids over the analysis period.

Pharmaceutical excipients help lipids achieve better functionalities, such as a longer shelf life, and improve formulation efficacy. Furthermore, rising demand in emerging economies is driving local drug production, which is boosting market sales. In addition, manufacturers are investing in R&D to develop specific products to enter the market.

Competitive Landscape

Prominent players in the Lipid Nanoparticles market are Merck KGaA, Evonik Industries AG, Gattefossé, Precision NanoSystems, IOI Oleo GmbH, Genevant Sciences, Exelead, Avanti Polar Lipids, Nippon Fine Chemicals Co. Ltd., Lipoid GmbH, Cargill, Incorporated, BASF SE, Archer Daniels Midland Company, Koninklijke DSM N.V., Kerry Group plc., Nordic Naturals, Inc., Clover Corporation, Croda International plc., Lipoid Kosmetik AG, and Omega Protein Corporation, among others.

Browse More@ https://www.futuremarketinsights.com/reports/lipid-nanoparticles-market

Key Segments Covered in the Lipid Nanoparticles Industry Analysis

Lipid Nanoparticles Market by Type:

  • Solid Lipid Nanoparticles (SLNs)
  • Nanostructured Lipid Carriers (NLCs)
  • Others

Lipid Nanoparticles Market by Application:

  • Therapeutics
  • Research

Lipid Nanoparticles Market by End-User:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Others

Comments

Post a Comment

Popular posts from this blog

Handheld Ultrasound Scanners Market Will Generate Booming Growth Opportunities to 2032

Image
According to industry predictions, the global Handheld Ultrasound Scanners Market Demand will increase at a CAGR of 9.1% from 2022 to 2032, reaching a value of US$ 472.1 million by the end of 2022. By 2032, sales are estimated to exceed a valuation of roughly US$ 1.1 billion. With an expected 83.6% market share in 2021, the wired modality now leads the sector. Because they connect to Bluetooth or Wi-Fi devices such as mobile phones or tablets, Handheld Ultrasound Scanners are gaining appeal among both medical professionals and non-radiologists. These devices improve networking systems and ease picture transfer to medical facilities. Global Handheld Ultrasound Scanners Market: Dynamics         Technological advancements in medical imaging devices, increased use of Handheld Ultrasound Scanners among non-radiologists, benefits from international trade agreements, increased importing of imaging diagnostics systems, increased use of Handheld Ultrasound Scanners in emergency medical service
Read more

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

Antidiabetics Market to reach US$ 223 billion by 2032, growing at a 9.6% CAGR from 2022 to 2032 | Future Market Insights, Inc.

Image
The global Antidiabetics Market is expected to earn US$ 223 billion while expanding at a CAGR of 9.6% during the forecast period. The rising prevalence of diabetes worldwide can be attributed to the market's expansion. The ageing baby boomer population is another factor driving the market during the forecast period. According to the International Diabetes Federation, the global diabetes incidence will increase from 366 million in 2011 to 552 million by 2030. During the forecast period, the industry is expected to benefit from a significant increase in the number of diabetic patients. Furthermore, new product development is expected to benefit the market in the near future. For example, Novo Nordisk, a Danish pharmaceutical company, announced the launch of oral semaglutide for the treatment of Type 2 diabetes in India in January 2022. Furthermore, the development of advanced pumps based on smart technologies like AI and ML is expected to open up a slew of new doors. For exampl
Read more